New Hyde Park, NYNCT07163793Now EnrollingIRB Ready

Acute Myeloid Leukemia in Remission Clinical Trial in New Hyde Park, NY

Access cutting-edge acute myeloid leukemia in remission treatment through this clinical trial at a research site in New Hyde Park. Study-provided care at no cost to qualified participants.

Sponsored by Northwell Health

Quick Self-Assessment

See if you qualify for this New Hyde Park location

Preparing your pre-screening questions…

Expert Care in New Hyde Park

Access acute myeloid leukemia in remission specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia in remission treatment provided free

Apply for This New Hyde Park Location

Check if you qualify for this acute myeloid leukemia in remission clinical trial in New Hyde Park, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Hyde Park

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Hyde Park site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia in Remission Study in New Hyde Park

Pilot Study of Reduced Venetoclax Exposure

Sponsor: Northwell Health

Who Can Participate

Inclusion Criteria

Stated willingness to comply with all study procedures and availability for the duration of the study
Ability to take oral medication and be willing to adhere to the study regimen
Diagnosed by current WHO or ICC criteria with Acute Myeloid Leukemia and treated for initial induction therapy with one of two regimens:
5-Azacitidine administered subcutaneously at a dose of 75mg/m2/day X 7 days in combination with VEN (21-28 days/cycle)
Decitabine administered intravenously at a dose of 20mg/m2/day administered in combination with VEN (21-28 days/cycle)
Achieving morphological CR/CRi by bone marrow biopsy with \<5% blasts within 3 cycles. See Appendix 2 for definitions.
Consent to be obtained within 10 days (+/- 3 days) of bone marrow biopsy report showing morphological remission. C1D1 of trial to be initiated within 10 days (+/- 7 days) of bone marrow biopsy report showing morphological remission.
Intensive treatment ineligible; transplant ineligible or refusal of transplant
Patient must be able to understand and sign informed consent and additional study documents
On C1D1 of trial, patient must have count recovery with ANC \>1000, platelets \> 50, Hemoglobin \> 7.7 and without transfusion support for 7 days.
No growth factor (G-CSF) use in 14 days prior to C1 D1 of trial.

Exclusion Criteria

Treatment with another investigational drug
Use of growth factor (G-CSF) within the last 14 days prior to C1D1 of trial treatment.
On concomitant targeted therapy such as FLT3 inhibitor or IDH1/2 inhibitor.
Subject has received treatment prior to induction with the following: i. Prior hypomethylating agent or BCL-2 inhibitor for either AML or MDS other than for induction prior to enrollment. ii. Prior CAR-T cell therapy. iii. Experimental or investigational drug therapy for 14 days prior to study entry leukemia-directed therapies.
Subject has: i. Acute promyelocytic leukemia (APL) with t(15;17). ii. Presence of t(9;22) given the potential indication for concurrent tyrosine kinase therapy. iii. Known active CNS involvement with AML.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Hyde Park?

Yes, this clinical trial (NCT07163793) has an active research site in New Hyde Park, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia in Remission Treatment Options in New Hyde Park, NY

If you're searching for acute myeloid leukemia in remission treatment options in New Hyde Park, NY, this clinical trial (NCT07163793) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Hyde Park research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia in remission specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia in remission clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in New Hyde Park, NY

See all leukemia clinical trials recruiting in New Hyde Park — not just this study.

Browse Leukemia Trials in New Hyde Park →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in New Hyde Park?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Hyde Park, NY